An observational study in Oxygen Deficiency, Acute Kidney Injury and Ovarian Carcinoma, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Recruiting at 1 site in Italy. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-07.
Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Hypoxia with a site in Italy — 4 open to participants now, 5 under way, none of them phase 3. Hypoxia · Italy.
Among the 26 studies in Hypoxia with a site in Italy, this one is one of 2 that started in 2024, is one of 7 observational ones, and was the 22nd registered.
1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.
Browse Hypoxia studies →4 of the 26 studies in Hypoxia with a site in Italy are open now. Recruiting first, the newest first:
Istituti Clinici Scientifici Maugeri SpA · Sites in Italy
Ages 18+
Università Vita-Salute San Raffaele · Sites in Italy
Ages 18–99
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+ · Women only
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 75 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 79 across 279 observational studies indexed under Hypoxia.
Median enrollment 48 across the 19 interventional studies, 400 across the 7 observational. Of the 16 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 26 have an industry lead sponsor. The 10 most frequent:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS is the lead sponsor of 953 studies on the registry; 541 are open to participants now.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS has 5 studies filed under Hypoxia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Hypoxia with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Tissue oximetry obtained from peripheral muscle measures the state of tissue oxygenation of various organs and, as already widely described in the literature, can be used to measure the state of kidney's tissue oxygenation. However, there is no evidence in the existing scientific literature on the use of muscle tissue oximetry in patients undergoing cytoreductive surgery for ovarian cancer with hyperthermic intraperitoneal chemotherapy.
The primary objective of our study is to evaluate whether there is a correlation between average intraoperative muscle tissue oximetry below 65% (a value which is considered critical in the literature for the resulting cellular damage) and postoperative renal damage in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for ovarian cancer.
Tissue oximetry obtained from peripheral muscle can be used to measure the state of kidney's tissue oxygenation.
50 Adult female patients ASA 1-2 undergoing cytoreductive surgery with laparoscopic or laparotomy technique (for ovarian cancer) associated with hyperthermic intraperitoneal chemotherapy will be enrolled.
The primary objective of our study is to evaluate whether there is a correlation between average intraoperative muscle tissue oximetry below 65% (a value which is considered critical in the literature for the resulting cellular damage) and postoperative renal damage (according to the AKIN and KIDGO classification) in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for ovarian cancer.
Secondary objectives are:
Adult female patients ASA 1-2 undergoing cytoreductive surgery with laparoscopic or laparotomy technique (for ovarian cancer) associated with hyperthermic intraperitoneal chemotherapy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Evaluation of a correlation between average intraoperative muscle tissue oximetry and postoperative renal damage in patients undergoing cytoreductive surgery with HIPEC for ovarian cancer
Also known as: Hemodynamics parameters with Hemosphere
Correlation between intraoperative tissue oximetry and postoperative acute renal injury.
An intraoperative mean tissue oximetry value of 65% or less is considered to predict cellular damage. Postoperative renal injury is classified according to AKIN and KIDGO criteria.
Time frame: Tissue oximetry is defined as TWA (time-weighted average) value resulted by values recorded intraoperatively every 20 minutes.
Tissue oximetry
Describing intraoperative variation of tissue oximetry expressed in percent.
Time frame: TWA value resulted by intraoperative values recorded every 20 minutes during surgery.
Tissue oximetry during hyperthermic intraperitoneal chemotherapy
Describing variation of tissue oximetry during hyperthermic intraperitoneal chemotherapy, expressed in percent.
Time frame: TWA value resulted by intraoperative values recorded every 20 minutes during hyperthermic intraperitoneal chemotherapy .
Emodinamic parameters (systolic, mean and diastolic pressures)
Describing mean values of intraoperative arterial pressure (systolic, mean and diastolic pressures), expressed in mmHg
Time frame: Intraoperatively, a mean value resulted by values recorded every 20 minutes during surgery.
Emodinamic parameters (systolic, mean and diastolic pressures) during hyperthermic intraperitoneal chemotherapy
Describing mean values of arterial pressure (systolic, mean and diastolic pressures), expressed in mmHg, during hyperthermic intraperitoneal chemotherapy
Time frame: A mean value resulted by values recorded every 20 minutes during hyperthermic intraperitoneal chemotherapy
Serum Creatinine level
Mean value of creatinine, daily assessed for the first 7 postoperative days, expressed in mg/dL
Time frame: From 1st to 7th postoperative days
Serum Blood urea nitrogen level
Mean value of Serum blood urea nitrogen, daily assessed for the first 7 postoperative days, expressed in mg/dL
Time frame: From 1st to 7th postoperative day
Serum sodium level
Mean values of Serum sodium, daily assessed for the first 7 postoperative days, expressed in mmol/L
Time frame: From 1st to 7th postoperative day
Serum Potassium level
Mean values of Serum potassium, daily assessed for the first 7 postoperative days, expressed in mmol/L
Time frame: From 1st to 7th postoperative day
Serum Chloride level
Mean values of Serum chloride, daily assessed for the first 7 postoperative days, expressed in mmol/L
Time frame: From 1st to 7th postoperative day
Serum Calcium level
Mean values of Serum calcium, daily assessed for the first 7 postoperative days, expressed in mmol/L
Time frame: From 1st to 7th postoperative day
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Aug 2025, 13 months after the start.
Of 125 non-industry observational studies under Hypoxia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 74. This study's planned 13 months is below that.
Counting every sponsor, half of 155 studies reached it within 14 months; a quarter within 3 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS →